CTR20262442 Human fibrinogen (Sinopharm Group Shanghai Blood Products) Deficiency Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262442 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 21 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262442 is a hot trial to watch
Deficiency Diseases is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262442 is notable because it evaluates Human fibrinogen (Sinopharm Group Shanghai Blood Products) in a Phase 3 design sponsored by Sinopharm Kunming Blood Products Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262442 |
| Official title | 评价人纤维蛋白原在成人先天性纤维蛋白原减少或缺乏症患者中的药代动力学及有效性和安全性的单臂、开放、多中心临床试验 |
| Phase / status | Phase 3 / 进行中 （招募中） |
| Intervention | Human fibrinogen (Sinopharm Group Shanghai Blood Products) |
| Sponsor | Sinopharm Kunming Blood Products Co., Ltd. |
| Geography | China |
| Enrollment | 2 |
| Primary endpoint | |
| Endpoint time frame | 首次输注试验药物 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Human fibrinogen (Sinopharm Group Shanghai Blood Products) in Deficiency Diseases.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of 2 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (首次输注试验药物) — 首次输注后的活性回收率（又称输注效率值）
- Primary endpoint (试验期间) — 急性出血和围手术期出血管理的止血疗效评价
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Trial-sourced asset: Human fibrinogen (Sinopharm Group Shanghai Blood Products). The Drug & Asset MCP enrichment step is designed to add normalized targets, modality and global development status when an exact asset match is available.
Trial-sourced sponsor: Sinopharm Kunming Blood Products Co., Ltd.. Company & Deal Intelligence MCP is the companion workflow for resolving organization identity, corporate profile and partnering context.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262442 provides a focused lens on Deficiency Diseases development. Its value will be determined by whether Human fibrinogen (Sinopharm Group Shanghai Blood Products) can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
